Collegium Pharmaceutical Inc buy tamam
Start price
21.06.18
/
50%
€24.70
Target price
03.06.19
€36.08
Performance (%)
-57.85%
End price
03.06.19
€10.41
Summary
This prediction ended on 03.06.19 with a price of €10.41. Massive losses of -57.85% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 0.709% | 0.709% | 24.561% | 39.216% |
| iShares Core DAX® | -0,20 % | 5,47 % | 9,19 % | 48,66 % |
| iShares Nasdaq 100 | 2,57 % | 10,09 % | 39,29 % | 95,72 % |
| iShares Nikkei 225® | 0,60 % | 9,87 % | 46,20 % | 63,77 % |
| iShares S&P 500 | 1,80 % | 7,40 % | 29,62 % | 67,24 % |
Comments by tamam for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
(Vom Mitglied beendet)